Together, these data suggest that in addition to targeting axons within lesions in MS patients, CD8+ T cells may target MHC class I–expressing neuronal cell bodies located in gray matter tissues and nonlesional white matter distal from the site of lesions. The gene discussed is CD8A; the disease is myeloid sarcoma.